Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat + mFOLFIRINOX + Bevacizumab in Metastatic Colorectal Cancer
NCT05070104Phase 1Withdrawn
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of devimistat in colorectal cancer (CRC), sponsored by Cornerstone Pharmaceuticals. Primary endpoints: Safety and tolerability and Recommended Phase 2 Dose. Planned start Mar 2023; status: withdrawn.
02
Drugs
devimistat
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05070104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070104.